Pacira BioSciences, Inc. is the holding company for its subsidiary, Pacira Pharmaceuticals, Inc. The Company has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.

• Revenue in USD (TTM)726.41m
• Net income in USD7.03m
• Incorporated2006
• Employees829.00

• Location
  Pacira Biosciences Inc2000 SIERRA POINT PARKWAY, SUITE 900BRISBANE 94005United StatesUSA
• Phone+1 (650) 242-8052
• Fax+1 (302) 655-5049
• Websitehttps://www.pacira.com/